---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-23-000054"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T13:11:29.726757+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lisata Q2 net loss $4.0M, extends cash runway to Q1 2026; tech transfer deal for TPN platform

## Summary
- Net loss $4.0M in Q2 2023 vs $6.6M in Q2 2022, down 40% due to $2.2M NJ tax credit.
- Cash and securities $57.6M; projected runway into Q1 2026 based on capital conservation measures.
- Signed technology transfer agreement for TPN platform with Impilo Therapeutics; receives equity stake, no future capital commitment.
- LSTA1 progress: ASCEND Phase 2b enrollment >70% target; BOLSTER trial open; iLSTA initiated in Australia.
- FDA granted orphan designation for LSTA1 in malignant glioma; GBM trial planned for Q4 2023.

## SEC filing metadata
- accession: 0000320017-23-000054
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001723000054/0000320017-23-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001723000054/clbs-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-23-000054
- JSON: https://secwatch.observer/filing/0000320017-23-000054.json
- Plain text: https://secwatch.observer/filing/0000320017-23-000054.txt

## Key facts
- Earnings Releases
  LISATA THERAPEUTICS, INC. reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000032001723000054/0000320017-23-000054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.